Clinical Trials Logo

Optic Neuropathy, Ischemic clinical trials

View clinical trials related to Optic Neuropathy, Ischemic.

Filter by:

NCT ID: NCT01768260 Recruiting - Clinical trials for Anterior Ischemic Optic Neuropathy

Effect of EECP on Anterior Ischemic Optic Neuropathy

AION
Start date: December 2012
Phase: N/A
Study type: Interventional

Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.

NCT ID: NCT01330524 Recruiting - Clinical trials for Acute Nonarteritic Anterior Ischemic Optic Neuropathy

Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo

Start date: January 2010
Phase: Phase 1/Phase 2
Study type: Interventional

In this study 16 Patients diagnosed with Nonarteritic Anterior Ischemic Optic Neuropathy(NSION) who had a sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn in less than 30 days without exclusion criteria are randomly divided in two groups 1) control 2) case. In case group Avastin and Triamcinolone will be injected trough vitreal and placebo will be injected in control group. BCVA and Visual field will be then measured in these two groups.

NCT ID: NCT00813059 Recruiting - Clinical trials for Non-arteritic Anterior Ischemic Optic Neuropathy

Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy

Start date: February 2009
Phase: Phase 2
Study type: Interventional

Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision. About 15% of patients will experience NAION in the second eye; many of these patients will be left legally blind. Currently, there is no treatment for NAION and for patients in whom the second eye becomes involved by the disease the outcome can be devastating. The investigators are conducting a study where the investigators will inject a medication into the involved eye of patients with NAION. This medication might decrease the swelling of the optic nerve and improve their vision in that eye.